EUVIMEDSkopri EUVIMED
Open access

Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection

Gabriela Baldeon Vaca iD, Michelle Meyer iD, Ana Cadete iD, Chiaowen Joyce Hsiao iD, Anne Golding, Albert Jeon, Eric Jacquinet, Emily Azcue iD, Chenxia Monica Guan, Xavier Sanchez-Felix, Colette A Pietzsch iD, Chad E Mire iD and 8 more

Science Advances · 2023-09-22 · 9 (38)

DOI: 10.1126/sciadv.adh1655 ↗

At a glance

Journal article in Science Advances, published on 2023-09-22. Written by Gabriela Baldeon Vaca and 19 co-authors. Institution: Moderna Inc., Cambridge, MA, USA. Major MEDLINE topics: COVID-19. Cited 88 times so far (Crossref); 51 references. The full text is freely available in PubMed Central.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Intranasal vaccination represents a promising approach for preventing disease caused by respiratory pathogens by eliciting a mucosal immune response in the respiratory tract that may act as an early barrier to infection and transmission. This study investigated immunogenicity and protective efficacy of intranasally administered messenger RNA (mRNA)–lipid nanoparticle (LNP) encapsulated vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Syrian golden hamsters. Intranasal mRNA-LNP vaccination systemically induced spike-specific binding [immunoglobulin G (IgG) and IgA] and neutralizing antibodies. Intranasally vaccinated hamsters also had decreased viral loads in the respiratory tract, reduced lung pathology, and prevented weight loss after SARS-CoV-2 challenge. Together, this study demonstrates successful immunogenicity and protection against respiratory viral infection by an intranasally administered mRNA-LNP vaccine.

Subjects

MeSH terms (MEDLINE)

COVID-19AnimalsCricetinaeSARS-CoV-2VaccinationAntibodies, NeutralizingRNA, Messenger

Substances

Antibodies, NeutralizingRNA, Messenger

Authors and institutions

  • Moderna Inc., Cambridge, MA, USA.
  • Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
  • Galveston National Laboratory, Galveston, TX, USA.
  • Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.

ORCID profiles: Gabriela Baldeon Vaca, Michelle Meyer, Ana Cadete, Chiaowen Joyce Hsiao, Emily Azcue, Colette A Pietzsch, Chad E Mire, Matthew A Hyde, Margaret E Comeaux, Alexander Bukreyev, Kapil Bahl

Cite

APA

Baldeon Vaca, G., Meyer, M., Cadete, A., Hsiao, C. J., Golding, A., Jeon, A., Jacquinet, E., Azcue, E., Guan, C. M., Sanchez-Felix, X., Pietzsch, C. A., Mire, C. E., Hyde, M. A., Comeaux, M. E., Williams, J. M., Sung, J. C., Carfi, A., Edwards, D. K., Bukreyev, A., & Bahl, K. (2023). Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection. Science Advances, 9(38). https://doi.org/10.1126/sciadv.adh1655

Vancouver

Baldeon Vaca G, Meyer M, Cadete A, Hsiao CJ, Golding A, Jeon A, et al. Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection. Science Advances. 2023;9(38). doi:10.1126/sciadv.adh1655

BibTeX
@article{BaldeonVaca2023,
  author = {Baldeon Vaca, Gabriela and Meyer, Michelle and Cadete, Ana and Hsiao, Chiaowen Joyce and Golding, Anne and Jeon, Albert and Jacquinet, Eric and Azcue, Emily and Guan, Chenxia Monica and Sanchez-Felix, Xavier and Pietzsch, Colette A and Mire, Chad E and Hyde, Matthew A and Comeaux, Margaret E and Williams, Julie M and Sung, Jean C and Carfi, Andrea and Edwards, Darin K and Bukreyev, Alexander and Bahl, Kapil},
  title = {Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection},
  journal = {Science Advances},
  year = {2023},
  volume = {9},
  number = {38},
  doi = {10.1126/sciadv.adh1655}
}
Start for free →